The US Food and Drug Administration's enhanced paragraph IV patent certification data continues to illustrate the varying interest of sponsors in developing generics, depending on the product.
A count of the potential first applicant ANDAs submitted, those with valid paragraph IV certifications for at least one patent in an NDA and eligible for 180-day exclusivity, will be...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?